Real-world study shows lenalidomide-dexamethasone yields 22.9-month PFS in transplant-ineligible myeloma
Real-world study shows lenalidomide treatment outcomes for older multiple myeloma patients
A prospective, non-interventional study of 168 transplant-ineligible NDMM patients in Germany found median PFS of 22.9 months and OS of 58.1…
Real-world data shows lenalidomide plus low-dose dexamethasone keeps older multiple myeloma patients disease-free for nearly two years while…
Review examines adoptive cellular therapies and immunoproteasome role in relapsed/refractory multiple myeloma
Review explores cellular therapies and immune system targeting for multiple myeloma
A systematic review discusses emerging evidence for adoptive cellular therapies (CAR T-cells, TCR-engineered T-cells) in relapsed/refractory…
Cellular therapies like CAR T-cells show promise for treating multiple myeloma, but severe side effects, high costs, and resistance limit th…
Phase 1 trial of WVT078 with/without WHG626 shows preliminary activity in relapsed/refractory multiple myeloma
Can a new combination therapy help when multiple myeloma returns?
A phase 1 dose-escalation trial in 56 patients with relapsed/refractory multiple myeloma assessed the BCMA×CD3 bispecific antibody WVT078 al…
Adding a second drug to a new antibody therapy nearly doubled response rates in early trials for patients with returning multiple myeloma.
Bisphosphonates reduce vertebral fracture risk in multiple myeloma, spinal cord compression effect unclear
Can bone drugs protect the spine in multiple myeloma? A new review weighs in.
A meta-analysis of 11 randomized trials in adults with multiple myeloma found bisphosphonates reduced vertebral fracture risk compared to no…
Bone drugs called bisphosphonates lower the risk of spine fractures in multiple myeloma patients, though evidence on preventing spinal cord …
FDA Approves Elrexfio for Relapsed or Refractory Multiple Myeloma After Four Prior Lines of Therapy
The FDA approved a new treatment for a type of blood cancer called multiple myeloma.
The FDA has approved Elrexfio, a bispecific BCMA-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myelom…
A new FDA-approved treatment helps shrink multiple myeloma in patients who have already tried at least four other therapies.
SVRD yields 89.7% ORR, 79.3% EMD resolution in NDMM with EMD in phase 2 trial
Can a new drug combination help people with aggressive multiple myeloma? Early results show promise.
In a phase 2 trial of 29 patients with newly diagnosed multiple myeloma and extramedullary disease (EMD), selinexor combined with VRD (SVRD)…
A new four-drug combination helped nearly 90% of patients with aggressive multiple myeloma shrink or eliminate cancer outside the bone marro…
Daratumumab + Len/Dex shows ORR in relapsed/refractory multiple myeloma phase 1/2 trial
Can a new drug combination help people with multiple myeloma that has returned after treatment?
This phase 1/2 study evaluated daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed-refracto…
A new three-drug combination of daratumumab, lenalidomide, and dexamasone showed safety and response in people with relapsed multiple myelom…